Shire sells cancer drugs to Servier as Takeda circles
Shire, the London-listed rare diseases specialist that is a potential takeover target for Japan's Takeda Pharmaceu.....»»
The Petri Dish: Beam"s acquisition; cancer startup gets $95M
While some in the life sciences industry create drugs and devices to tackle the Co.....»»
First non-Japanese CEO of Takeda has set out 2 objectives: to be an R&D-driven firm and to build global scale
The 240-year old biopharma company reinforced its global ambition in 2019 with the $62 billion acquisition of pharma firm Shire Takeda Pharmaceutical Co. Chief Executive Officer Christophe Weber speaks during a press confere.....»»
Office building that counts Mercy Health as a tenant sells for $32.5M
The 75,000-square-foot, three-story complex houses Mercy Health-Cincinnati, Cincinnati Eye Institute and OHC, a physician practice that specializes in adult cancer and blood disorders......»»
Philadelphia biotech firm acquired for $78M by North Carolina company with eye on cancer treatment
The North Carolina biopharmaceutical firm is aiming to boost its pipeline of drugs designed to combat recurrent glioma – a form of brain cancer......»»
Duke researchers find key link between lung, brain cancer
Researchers at Duke University say they've found a breakthrough for lung and brain cancer treatment – a potential pathway that could lead to new drugs......»»
The Week Ahead In Biotech: 2 IPOs Plus FDA Decisions On Moderna"s COVID Vaccine And Drugs From Amgen, MacroGenics
Biotech stocks advanced for a third straight week, defying the broader market weakness. The space got solid support from positive stock reactions to presentations made at hematology and breast cancer conferences. read more.....»»
Gilead, Takeda Rumored to Have Sights on Iovance
Potential suitors looking to expand their work in cancer likely covet company's technologyRelated Stocks: IOVA, GILD, TAK, CLLS,.....»»
J&J beats profit estimates but coronavirus fuels forecast cut
Johnson & Johnson on Tuesday beat analysts' estimates for first-quarter profit on higher sales of its cancer drugs and consumer products including Tylenol, while cutting its full-year forecast due to coronavirus shutdowns......»»
The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak.....»»
Gilead buys Forty Seven for $4.9 billion to bolster cancer drug pipeline
Gilead Sciences Inc said on Monday it would buy Forty Seven Inc for $4.9 billion in cash, adding an experimental treatment that targets blood cancer to its portfolio of oncology drugs......»»
Bayer cools prospect of imminent glyphosate settlement
German drugs and pesticides company Bayer was at pains on Thursday to quell expectations it was nearing an out-of-court settlement laying to rest claims its glyphosate-based weedkillers cause cancer......»»
Bayer chairman quits after making progress to settle litigation
Bayer , which is fighting claims its weedkiller Roundup causes cancer, said its Chairman Werner Wenning was stepping down because the drugs and crop protection company was making good progress in settlement talks......»»
Revolution Medicines Joins Amgen and Mirati in Quest for New Type of Cancer Drugs
Company’s shares up 70% just days after public offeringRelated Stocks: RVMD, AMGN, SNY, MRTX, JNJ, MRNA, BBIO, CNST,.....»»
Japan"s Takeda forecasts surprise full-year operating profit
Takeda Pharmaceutical Co Ltd said it now expects an operating profit for the full year, as opposed to its earlier projection for a loss, due to stronger sales and cost savings from its integration with Shire Plc......»»
Johnson & Johnson misses revenue estimates as blockbuster drugs disappoint
Johnson & Johnson narrowly missed quarterly revenue estimates on Wednesday as sales of its blockbuster psoriasis medicine Stelara and cancer drug Imbruvica fell short of expectations......»»
J&J misses revenue estimates as blockbuster drugs disappoint
Johnson & Johnson narrowly missed quarterly revenue estimates on Wednesday as sales of its blockbuster psoriasis medicine Stelara and cancer drug Imbruvica fell short of expectations......»»
Johnson & Johnson quarterly profit jumps 32%
Johnson & Johnson on Wednesday posted a 32% rise in fourth-quarter profit, boosted by demand for its cancer drugs Darzalex and Imbruvica......»»
Dow Jones Newswires: AstraZeneca: FDA gives orphan drug status to two liver cancer drugs
Imfinzi and tremelimumab were given orphan drug status as treatments for hepatocellular carcinoma, or HCC......»»
GlaxoSmithKline CEO expects to get "at least" six drug approvals from the FDA in 2020
GlaxoSmithKline CEO Emma Walmsley told "Mad Money" host Jim Cramer the British drugmaker has received "positive data" for cancer and HIV drugs......»»